Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis

Update Il y a 4 ans
Reference: NCT00141830

Woman and Man

Extract

The primary objective of this study is to compare the efficacy and safety of 3 dose levels of oral ERB-041 administered daily for 12 weeks versus placebo in subjects with active rheumatoid arthritis who have had a suboptimal response to therapy with stable doses of methotrexate (MTX).


Inclusion criteria

  • Rheumatoid Arthritis


Links